Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.12 USD | -0.08% | -4.11% | +28.91% |
Financials (USD)
Sales 2024 * | 69.71M | Sales 2025 * | 72.54M | Capitalization | 257M |
---|---|---|---|---|---|
Net income 2024 * | -125M | Net income 2025 * | -117M | EV / Sales 2024 * | 3.69 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.54 x |
P/E ratio 2024 * |
-2.09
x | P/E ratio 2025 * |
-2.43
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.91% |
Latest transcript on Enanta Pharmaceuticals, Inc.
1 day | +0.08% | ||
1 week | -4.11% | ||
Current month | -11.72% | ||
1 month | -8.93% | ||
3 months | -6.62% | ||
6 months | +32.86% | ||
Current year | +28.91% |
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 03-08-31 |
Chief Tech/Sci/R&D Officer | 50 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 20-06-28 |
Lesley Russell
BRD | Director/Board Member | 63 | 16-11-17 |
Bruce Carter
CHM | Chairman | 80 | 13-11-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 12.13 | -7.12% | 267 890 |
24-05-16 | 13.06 | -2.10% | 98,026 |
24-05-15 | 13.34 | +0.76% | 73,127 |
24-05-14 | 13.24 | +2.56% | 115,909 |
24-05-13 | 12.91 | +2.06% | 164,038 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.91% | 257M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- ENTA Stock